Abstract
Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.
Keywords:
BRAF; binimetinib; encorafenib; non-small cell lung cancer; podcast.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
-
Benzimidazoles* / administration & dosage
-
Benzimidazoles* / therapeutic use
-
Carbamates* / administration & dosage
-
Carbamates* / therapeutic use
-
Carcinoma, Non-Small-Cell Lung* / drug therapy
-
Carcinoma, Non-Small-Cell Lung* / genetics
-
Carcinoma, Non-Small-Cell Lung* / pathology
-
Humans
-
Lung Neoplasms* / drug therapy
-
Lung Neoplasms* / genetics
-
Lung Neoplasms* / pathology
-
Mutation*
-
Neoplasm Metastasis
-
Proto-Oncogene Proteins B-raf* / genetics
-
Sulfonamides* / administration & dosage
-
Sulfonamides* / therapeutic use
Substances
-
encorafenib
-
Benzimidazoles
-
Proto-Oncogene Proteins B-raf
-
Carbamates
-
Sulfonamides
-
binimetinib
-
BRAF protein, human